Up-regulation of endothelin type B receptors in the human internal mammary artery in culture is dependent on protein kinase C and mitogen-activated kinase signaling pathways by Nilsson, David et al.
BioMed  Central
Page 1 of 10
(page number not for citation purposes)
BMC Cardiovascular Disorders
Open Access Research article
Up-regulation of endothelin type B receptors in the human internal 
mammary artery in culture is dependent on protein kinase C and 
mitogen-activated kinase signaling pathways
David Nilsson1, Lotta Gustafsson1, Angelica Wackenfors1, Bodil Gesslein1,2, 
Lars Edvinsson1, Per Paulsson3, Richard Ingemansson3 and 
Malin Malmsjö*1,2
Address: 1Department of Medicine, Lund University Hospital, Sweden, 2Department of Ophthalmology, Lund University Hospital, Sweden and 
3Department of Cardiothoracic Surgery, Lund University Hospital, Sweden
Email: David Nilsson - david.nilsson@med.lu.se; Lotta Gustafsson - lotta.gustafsson@med.lu.se; 
Angelica Wackenfors - angelica.wackenfors@med.lu.se; Bodil Gesslein - bodil.gesslein@med.lu.se; Lars Edvinsson - lars.edvinsson@med.lu.se; 
Per Paulsson - per.paulsson@skane.se; Richard Ingemansson - richard.ingemansson@skane.se; Malin Malmsjö* - malin.malmsjo@med.lu.se
* Corresponding author    
Abstract
Background: Up-regulation of vascular endothelin type B (ETB) receptors is implicated in the
pathogenesis of cardiovascular disease. Culture of intact arteries has been shown to induce similar
receptor alterations and has therefore been suggested as a suitable method for, ex vivo, in detail
delineation of the regulation of endothelin receptors. We hypothesize that mitogen-activated
kinases (MAPK) and protein kinase C (PKC) are involved in the regulation of endothelin ETB
receptors in human internal mammary arteries.
Methods: Human internal mammary arteries were obtained during coronary artery bypass graft
surgery and were studied before and after 24 hours of organ culture, using in vitro pharmacology,
real time PCR and Western blot techniques. Sarafotoxin 6c and endothelin-1 were used to examine
the endothelin ETA and ETB receptor effects, respectively. The involvement of PKC and MAPK in
the endothelin receptor regulation was examined by culture in the presence of antagonists.
Results: The endohtelin-1-induced contraction (after endothelin ETB receptor desensitization) and
the endothelin ETA receptor mRNA expression levels were not altered by culture. The sarafotoxin
6c contraction, endothelin ETB receptor protein and mRNA expression levels were increased after
organ culture. This increase was antagonized by; (1) PKC inhibitors (10 μM bisindolylmaleimide I
and 10 μM Ro-32-0432), and (2) inhibitors of the p38, extracellular signal related kinases 1 and 2
(ERK1/2) and C-jun terminal kinase (JNK) MAPK pathways (10 μM SB203580, 10 μM PD98059 and
10 μM SP600125, respectively).
Conclusion: In conclusion, PKC and MAPK seem to be involved in the up-regulation of endothelin
ETB receptor expression in human internal mammary arteries. Inhibiting these intracellular signal
transduction pathways may provide a future therapeutic target for hindering the development of
vascular endothelin ETB receptor changes in cardiovascular disease.
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Background
Endothelin-1 is a potent vasoconstrictor produced by
endothelial cells. It is a vasoactive agent that mediates
multiple vascular actions and plays an important role in
hypertension and cardiovascular diseases by promoting
changes in vascular reactivity and endothelial function,
cardiovascular fibrosis, tissue remodeling, inflammation,
and oxidative stress. Endothelin exerts its effect through
two different G protein coupled receptors, the endothelin
type A (ETA) receptor and the endothelin type B (ETB)
receptor [1-3]. The endothelin ETA receptors are expressed
in vascular smooth muscle cells and mediate vasoconstric-
tion. In healthy conditions, endothelin ETB receptors are
mainly located on endothelial cells and mediate vasodila-
tation via the release of nitric oxide, prostaglandins and
endothelium-derived hyperpolarizing factor [4-6]. How-
ever, endothelin ETB receptors on vascular smooth muscle
cells have been observed to be upregulated during patho-
logical conditions such as atherosclerosis [7], congestive
heart failure [8], ischemic heart disease [9] and hyperten-
sion [10]. Endothelin receptors on vascular smooth mus-
cle cells are both mitogenic, leading to atherosclerosis,
and mediate strong vasoconstriction which may lead to
elevated vascular tone frequently observed in cardiovascu-
lar disease.
Endothelin receptor regulation can be studied in detail, ex
vivo, using organ culture of intact arteries. Endothelin ETB
receptors on smooth muscle cells are up-regulated when
whole blood vessels are incubated for 12 to 48 hours [11].
Furthermore, endothelin ETB receptors are up-regulated in
human coronary arteries after organ culture, in a similar
way as in ischemic heart disease in man [12]. Endothelin
receptor-changes also occur during organ culture in rat
cerebral and peripheral arteries, mimicking that observed
in peripheral artery disease, stroke and subarachnoidal
haemorrhage [13-15]. Detailed delineation of the regula-
tion of vascular endothelin receptors can be performed by
culture in the presence of different humoral factors or
intracellular signal transduction pathway inhibitors.
We aim to identify the intracellular signal transduction
pathways that regulate the expression of endothelin recep-
tors in the vasculature. These may provide future thera-
peutic targets for hindering the development of vascular
endothelin receptor changes in cardiovascular disease. In
a previous study, culture of porcine coronary arteries
shows that protein kinase C (PKC) and mitogen activated
protein kinases (MAPKs) are signaling pathways that reg-
ulate endothelin receptor expression [16]. Other studies,
using rat cerebral arteries, show similar results [17,18].
Hitherto, the regulation of endothelin receptors have
mainly been studied in animals and data from humans
barely exists. When identifying new targets for pharma-
ceutical intervention, it is of importance that the research
is performed not only in animals, but also in patients. In
the present study, internal mammary arteries from
patients undergoing coronary artery bypass graft surgery
were studied to examine the role of PKC and MAPK in the
endothelin ETA and ETB receptor regulation in humans.
PKC is a family of serine/threonine kinases participating
in signal transduction events in response to specific hor-
monal, neuronal and growth factor stimuli. MAPKs repre-
sent another group of serine/threonine kinases that are
thought to act downstream from PKC in the smooth mus-
cle cell regulatory cascade [19]. There are three major
groups of distinctly regulated MAPKs leading to altered
gene expression in humans. The extracellular signal
related kinases 1 and 2 (ERK1/2), the C-jun terminal
kinase (JNK) and the p38 MAPK are known to play impor-
tant roles in the intracellular signalling in response to
extracellular stimuli [20]. Upon activation, MAPKs cause
phosphorylation and activation of transcription factors
present in the cytoplasm or nucleus, thereby leading to
expression of target genes resulting in biological responses
[21].
In the present study, we use the organ culture model to
examine the involvement of PKC and MAPK pathways in
the regulation of endothelin receptors in the human inter-
nal mammary artery. Arterial segments are cultured for 24
hours in the absence or presence of PKC inhibitors (Ro-
32-0432 and bisindolylmaleimide I) and inhibitors of the
three major MAPK pathways in mammals (p38 MAPK,
ERK1/2 and JNK). The contractile effects and the levels of
endothelin ETA  and ETB  receptor protein and mRNA
expression are evaluated using in vitro pharmacology, real
time PCR and Western blot techniques.
Methods
Tissue collection
During coronary artery bypass graft surgery, one end of
the left mammary artery is harvested and sutured to the
coronary artery, distal to the stenosis. A segment of the
artery is sometimes removed when the artery is adjusted
to an appropriate length for the grafting procedure. The
artery segment that is removed can be used for research
without affecting the patient. For the present study, the
left internal mammary artery, from 27 patients undergo-
ing coronary artery bypass graft surgery, was used for
experimental analysis. The patients' median age was 70
years and ranged from 43 to 85 years. Twenty-one men
and 6 women were included in the study. After dissection
during surgery, the vessels were immediately immersed
into cold sterile Dulbeccos' modified Eagles' medium
(DMEM), transported to the laboratory on dry ice and
used for the experiments. In the laboratory, the arteries
were dissected free from adhering tissue, and then cut into
cylindrical segments (3–4 mm long).BMC Cardiovascular Disorders 2008, 8:21 http://www.biomedcentral.com/1471-2261/8/21
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Ethics
The study was approved by the Ethics Committee of Lund
University in Sweden and is in accordance with the Decla-
ration of Helsinki.
Organ culture procedure
The artery segments were divided into two groups; one
that was not cultured (control) and one that was cultured
for 24 hours. The artery segments for culture were placed
in a 48 well plate, one segment in each well, containing 1
ml DMEM and incubated for 24 hours at 37°C in humid-
ified 5% CO2 in air. DMEM (Gibco BRL, Praisley, UK) was
serum free and contained D-glucose (1 g/l), sodium pyru-
vate (100 mg/l) and was supplemented with penicillin
(100 U/ml), streptomycin (100 μg/ml) and amphotericin
B (0.25 μg/ml). The method of blood vessel culture has
been described previously [11]. The segments were cul-
tured in the absence or presence of:
(1) PKC inhibitors
￿ Ro-32-0432 (10 μM), 2-8-[(Dimethylamino)methyl]-
6,7,8,9-tetrahydropyrido [1,2-a]indol-3-yl}-3-(1-methyl-
1H-indol-3-yl)maleimide.
￿ Bisindolylamaleimide I (10 μM), 2-[1-(3-Dimethylami-
nopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide.
(2) MAPK inhibitors
￿ The p38 MAPK inhibitor, SB 203580 (10 μM), 4-(4-
Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-
1H-imidazole.
￿ The ERK1/2 inhibitor, PD 98059 (10 μM), 2-(2-Amino-
3-methoxyphenyl)-4H-1-benzopyran-4-one.
￿ The JNK inhibitor, SP600125 (10 μM), 1,9-Pyrazoloan-
throne Anthrapyrazolone.
In vitro pharmacology
For the in vitro pharmacology experiments, the arterial
segments were mounted on two L-shaped metal prongs,
one of which was connected to a force displacement trans-
ducer for continuous recording of the isometric tension
[22]. The mounted segments were immersed in tempera-
ture controlled (37°C) tissue baths containing a bicarbo-
nate based buffer solution of the following composition;
NaCl (119 mM), NaHCO3 (15 mM), KCl (4.6 mM), MgCl
(1.2 mM), NaH2PO4 (1.2 mM), CaCl2, (1.5 mM) and glu-
cose (5.5 mM), which was continuously gassed with 5 %
CO2 in O2 resulting in a pH of 7.4. Eight to sixteen seg-
ments were studied at the same time in separate tissue
baths. The segments stabilized at a resting tension of 4
mN for one hour before the experiments were started. Pre-
vious results show that a resting tension of 3 to 5 mN pro-
vides optimal conditions for studying vascular
contraction in the human left internal mammary artery
[23]. The contractile capacity of each arterial vessel seg-
ment was examined by exposure to a potassium rich (63.5
mM) buffer solution.
The endothelin ETB receptor agonist, sarafotoxin 6c, was
first added at increasing concentrations (10-11-10-6 mM).
The arteries were washed and endothelin-1 was therafter
added at increasing concentrations (10-11-10-6 mM). At
this stage the endothelin ETB receptors were desensitized
[24], allowing endothelin-1 to act selectively on endothe-
lin ETA receptors.
The sarafotoxin 6c experiments were run in the absence
(control) and presence of the selective endothelin ETB
receptor antagonist BQ788 ((N-cis-2,6-dimethyl-piperidi-
nocarbonyl-L-γ-methylleucyl-D-1-methoxycarbonyltryp-
tophanyl-D-norleucine, 0.1 μM), added 15 min prior to
sarafotoxin 6c.
Previous results from human internal mammary arteries
show a variation in the expression of the vasoconstricting
endothelin ETB receptors and only 58 % of the patients
that undergo coronary artery bypass graft surgery have
graft vessels that express these receptors [23]. Other stud-
ies have shown similar irregularity in the endothelin
response [25]. In the present study, 44 % of the examined
arteries (patients) responded to sarafotoxin 6c. For the in
vitro pharmacology experiments, using BQ788, only the
arteries that responded to sarafotoxin 6c was used. For the
other experiments, both the arteries that responded and
the arteries that did not respond to sarafotoxin 6c were
used for the experiments, calculations and results.
All drugs for the in vitro pharmacological experiments
were purchased from Sigma Chemical Co (St. Louis, MO).
Endothelin-1 and sarafotoxin 6c were dissolved in 0.9 %
NaCl with 10 % albumin and BQ788 were dissolved in
0.9 % saline. The PKC and MAPK inhibitors were dis-
solved in dimethylsulphoxide (0.01 M DMSO in 0.9 %
saline, Calbiochem ®, Darmstadt, Germany).
Real time PCR
The arteries for real time PCR experiments were frozen in
liquid nitrogen and stored at -80°C until the experiments
were performed. Endothelin ETA and ETB receptor mRNA
expression levels were quantified by real time PCR. Total
cellular RNA was extracted using TRIzol®LS according to
the supplier's instructions (Life Technologies, Paisley,
UK). Reverse transcription of total RNA to cDNA was car-
ried out using the Gene Amp RNA PCR kit in a DNA Ther-
mal cycler (Perkin-Elmer Applied Biosystems, Foster City,
CA, USA). Real time PCR was performed with the Gene-
Amp SYBR Green PCR kit (PE Applied Biosystems) in a
Perker-Elmer real time PCR machine 7300.BMC Cardiovascular Disorders 2008, 8:21 http://www.biomedcentral.com/1471-2261/8/21
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The cDNA synthesized above served as template in a (25
μl) reaction. A non-template control was included in all
experiments. The GeneAmp 7300 sequence detection sys-
tem monitored the binding of a fluorescent dye to double-
strand DNA by real time detection of the fluorescence dur-
ing each cycle of PCR amplification. Specific primers were
designed as follows:
ETA  receptor GenBank: NM_001957 forward; 5'-ATT-
GCCCTCAGCGAACAC-3' reverse; 5'-CAACCAAGCA-
GAAAGACGGTC-3' ETB receptor GenBank: NM_000115
forward; 5'-GATACGACAACTTCCGCTCCA-3' reverse; 5'-
GTCCACGATGAGGACAATGAG-3'  β-actin GenBank:
NM_001101 forward; 5'-AAGGCCAACCGCGAGAA-3'
reverse; 5'-ACAGCC TGGATAGCAACGTACA-3' GAPDH
GenBank: NM_002046 forward; 5'-CACCAGGGCT-
GCTTT TAACTCT-3' reverse; 5'-CTTGACGGTGCCAT-
GGAATT-3'
The housekeeping genes, β-actin and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were used as refer-
ences due to their continuous expression in cells. The real
time PCR reaction was performed at a temperature of
50°C for 2 min, 95°C for 10 min, and the following 40
PCR cycles with 95°C for 15 s and 60° for 1 min. Oligo-
nucleotides and reagents for the PCR assay were pur-
chased from Perkin-Elmer, Applied Biosystems Foster
City, CA, USA.
Western Blot
Preparation of cell lysates
Whole cell extracts from the human internal mammary
arteries were prepared by adding 300 μl of RIPA buffert
(50 mM Tris, pH 8.0, 1.0% Igepal CA-630, 0.5% sodium
deoxycholate, 0.1% SDS, 150 mM NaCl) supplemented
with 0.37 g/ml Complete protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany). By using a
Tissue Lyser (Retsch GmbH, Haan, Germany) the samples
were homogenized for 3 minutes at maximum frequency.
Thereafter, the samples were incubated for 2 hours under
gentle rocking at 4°C, where after the samples were centri-
fuged at 12 000 g for 20 min and the supernatant was col-
lected for protein concentration determination (Protein
Assay Dye, Bio Rad, CA, USA).
Experimental procedure
Cell extracts were denatured in LDS sample buffer for 5
min in 95°C, run on SDS-PAGE (NUPAGE, 4–12% Bis-
Tris, Invitrogen, Carlsbad, CA, USA) and blotted onto
PVDF membrabes (0.2 μm, Invitrogen). Membranes were
blocked with 2% non-fat dried milk for 1 hour and incu-
bated with 1:100 goat polyclonal antibodies to human
ETB receptor (C-20, sc-21196, Santa Cruz Biotechnology,
Santa Cruz, Ca, USA) and 1:1000 HRP-coupled donkey
anti-goat secondary antibody (DakoCytomation, Glos-
trup, Denmark). The membrane was developed by using
the ECL Plus Western Blotting Reagent (GE Healthcare,
Little Chalfont, UK) and Fuji Film LAS-1000 equipment
(Fuji Film, Tokyo, Japan). Parallel membranes were incu-
bated with 1:5000 mouse monoclonal antibodies to beta-
actin (C4, sc-47778, Santa Cruz Biotechnology) and HRP-
coupled rabbit anti-mouse secondary antibody (DakoCy-
tomation). Primary and secondary antibody solutions
were prepared in PBS solution containing 2% bovine
serum albumin 0.1% Tween-20. After incubation with
antibodies, the membranes were washed 3 times and 5
min in PBS containing 0.1% Tween-20.
Calculations and statistics
Calculations and statistics were performed using Graph
Pad 4.0 software. Statistical analysis was performed using
Student's t-test when comparing two groups and ANOVA
with Dunnett's post-test for multiple comparisons when
comparing three groups or more. P < 0.05 was considered
significant. The results are expressed as mean ± standard
error of the mean (S.E.M.).
In vitro pharmacology
The maximum contraction (Emax) was calculated as per-
centage of the contractile capacity of 63.5 mM potassium.
The negative logarithm of the concentration that elicited
50% contraction (pEC50) was determined by linear regres-
sion analysis using the values immediately above and
below half-maximum response.
Real time PCR
The amount of endothelin ETA and ETB receptor mRNA
expression was calculated as relative to the amount
GAPDH or β-actin in the same sample by the formula X0/
R0 = 2CtR-CtX, where X0 = amount of endothelin ETB
mRNA, R0 = original amount of GAPDH or β-actin mRNA,
CtR = Ct value for GAPDH or β-actin and CtX = Ct value
for the endothelin ETA and ETB receptor mRNA.
Results
Effects of organ culture on endothelin ETA and ETB 
receptors
The endothelin ETB receptor mediated contraction was
studied using the selective agonist sarafotoxin 6c. The
endothelin-1-induced vasoconstriction was studied after
desensitizing the endothelin ETB receptors with sarafo-
toxin 6c prior to adding endothelin-1, leaving only
endothelin ETA receptors to respond.
Endothelin-1 induced potent contractions in the human
internal mammary arteries studied (Fig. 1). In vitro phar-
macology and real-time PCR experiments demonstrated
similar endothelin-1 contractions and endothelin ETA
receptor mRNA levels before and after organ culture (P =
n.s., n = 27 and 8 respectively, Fig. 1).BMC Cardiovascular Disorders 2008, 8:21 http://www.biomedcentral.com/1471-2261/8/21
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The endothelin ETB  receptor agonist, sarafotoxin 6c,
induced contraction in 44 % of the left internal mammary
arteries (patients) studied (n = 27). The sarafotoxin 6c
contraction was inhibited by the selective endothelin ETB
receptor antagonist, BQ788 (P < 0.05, n = 6, Fig. 2). Both
the arteries that responded and the arteries that did not
respond to sarafotoxin 6c were used for further experi-
ments, as described below.
The efficacy of the sarafotoxin 6c-contraction was signifi-
cantly increased after culture (p < 0.01, n = 27, Fig. 3) sug-
gesting up-regulated endothelin ETB receptors. Similarly,
Western blot and real time PCR experiments demon-
strated elevated levels of endothelin ETB receptor protein
and mRNA expression, respectively, after culture (P <
0.05, n = 6, Figure 4).
For the real time PCR experiments, similar patterns of
endothelin ETA and ETB receptor mRNA expression could
be shown when using β-actin as the reference gene as
when using GAPDH (data not shown), indicating that
these genes were trustworthy as references.
Inhibition of PKC
The increased sarafotoxin 6c contraction and endothelin
ETB receptor protein and mRNA expression levels during
organ culture were inhibited when the arteries were cul-
tured in the presence of the PKC inhibitors, Ro-32-0432
(10 μM) and bisindolylmaleimide I (10 μM). For results,
numbers and statistics, see Fig. 3 and 4.
Inhibition of MAPK
The p38 MAPK pathway inhibitor, SB203580 (10 μM),
the ERK1/2 pathway inhibitor, PD98059 (10 μM) and the
JNK pathway inhibitor, SP600125 (10 μM), inhibited the
(A) Endothelin-1 contractions (after ETB receptor desensitisation) and (B) ETA receptor mRNA levels in cultured and non-cul- tured human internal mammary arteries, examined using in vitro pharmacology (n = 27) and real time PCR (n = 8) experiments Figure 1
(A) Endothelin-1 contractions (after ETB receptor desensitisation) and (B) ETA receptor mRNA levels in cul-
tured and non-cultured human internal mammary arteries, examined using in vitro pharmacology (n = 27) and 
real time PCR (n = 8) experiments. The results are shown as mean values ± S.E.M. Statistical analyses, comparing cultured 
with non-cultured, were performed using Student's t-test. There were no significant differences.
Contractile responses elicited by cumulative application of  sarafotoxin 6c in non-cultured segments of human internal  mammary arteries in the absence (control) and presence of  0.1 μmol/l BQ788 Figure 2
Contractile responses elicited by cumulative applica-
tion of sarafotoxin 6c in non-cultured segments of 
human internal mammary arteries in the absence 
(control) and presence of 0.1 μmol/l BQ788. The 
results are shown as mean values ± S.E.M of six experiments. 
Statistical analyses of the maximum contraction, comparing 
control with BQ 788, was performed using Student's t-test, 
where P < 0.05 (*) was considered significant.BMC Cardiovascular Disorders 2008, 8:21 http://www.biomedcentral.com/1471-2261/8/21
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up-regulation of sarafotoxin 6c contraction, endothelin
ETB receptor protein and mRNA expression. For results,
numbers and statistics, see Fig. 5 and 6.
Discussion
Main findings
Up-regulation of vascular endothelin ETB  receptors is
implicated in the pathogenesis of cardiovascular disease.
This study demonstrates that the PKC and MAPK intracel-
lular signal transduction pathways may play a role in the
regulation of endothelin ETB receptors in the human inter-
nal mammary artery.
Organ culture and endothelin receptor regulation
The organ culture method, used in the present study, stim-
ulate up-regulation of endothelin ETB receptors in the
human left internal mammary artery, as shown by in vitro
pharmacology, Western blot and real time PCR experi-
ments. This is in accordance with our previous findings
that endothelin ETB  receptors are up-regulated during
organ culture in human coronary arteries [9]. This
increase in ETB receptor density can be compared to that
observed in arteries from patients with ischemic heart dis-
ease or hypertension [7,9,10]. Plasma levels of endothelin
are elevated in ischemic heart disease and in heart failure
[26,27]. Enhanced activity in the endothelin system has
been associated with the progression of cardiovascular
disease.
Endothelin is a strong vasoconstrictor and up-regulation
of endothelin receptors on vascular smooth muscle cells
causes inappropriate contraction that exacerbates athero-
sclerotic stenoses. Endothelin constricts human coronary
arteries, especially those with atherosclerosis, and
accounts for nearly all the resting tone at coronary artery
stenosis [28]. Endothelin is also known to act as a
mitogen on vascular smooth muscle cells, stimulate extra-
cellular matrix synthesis and attract monocytes in the
process of atherosclerosis.
We believe that it is important to gain insight into the reg-
ulation of the vascular endothelin receptor expression.
Identifying the intracellular signal transduction pathways
involved in the up-regulation of endothelin receptors may
provide new pharmaceutical targets. Organ culture is an
experimental model in which the endothelin receptor reg-
ulation can be studied in detail, ex vivo, to delineate the
molecular mechanisms involved. Culture in the presence
of different humoral factors or intracellular messenger
inhibitors may reveal important pathways involved in the
regulation of endothelin receptors. The method of organ
culture combines the advantage of cell culturing tech-
niques with the advantage of functional evaluation of
intact blood vessels.
Increased endothelin ETB contraction after organ culture
in the present study is presumably due to increased levels
Contractile responses elicited by cumulative application of the endothelin ETB receptor agonist sarafotoxin 6c in segments of  human internal mammary arteries Figure 3
Contractile responses elicited by cumulative application of the endothelin ETB receptor agonist sarafotoxin 6c 
in segments of human internal mammary arteries. The arterial segments were either not cultured or cultured in the 
absence or presence of the protein kinase C inhibitors (A) Ro-32-0432 or (B) bisindolylmaleimide I. The results are shown as 
mean values ± S.E.M of six experiments. Statistical analysis was performed using ANOVA with Dunnett's post-test for multiple 
comparisons. P < 0.05 (*) and P < 0.01 (**) was considered significant. Comparisons were made between the results from 
arteries exposed to culture with and without Ro-32-0432 or bisindolylmaleimide I.BMC Cardiovascular Disorders 2008, 8:21 http://www.biomedcentral.com/1471-2261/8/21
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of contractile endothelin ETB receptors on the vascular
smooth muscle cells. Previous results from our group
show that the contractile response to sarafotoxin 6c in the
human internal mammary artery is not significantly
affected by removal of the endothelium [10]. This is in
accordance with the current data since the arteries are
obtained from patient with advanced coronary artery dis-
ease and probably generalized atherosclerosis and
endothelium dysfunction.
Mechanisms governing the regulation of endothelin ETB 
receptors
We do not know the exact mechanism by which the
endothelin ETB receptors are up-regulation in culture. Pre-
vious experiments suggest that the up-regulation requires
physiological oxygen and glucose levels and that the
choice of buffer solution (Krebs or DMEM) does not seem
to play a role [29]. The dissection procedure is similar for
the non-cultured and cultured arteries and does presuma-
bly not play a role for the organ culture effects. The only
difference between the non-cultured and cultured vessel
segments is incubation per se. During incubation, per-
fusion pressure is lost and we speculate that this loss in
sheer stress may be one factor that triggers the receptor
regulation. Indeed, preliminary perfusion experiments in
vitro revile that the regulation of endothelin ETB receptors
is dependent on the perfusion pressure applied (not pub-
lished data). Up-regulation of ETB receptors is known to
rely on increased transcription and subsequent transla-
tion of ETB receptor mRNA [30]. This is in accordance with
the present results that demonstrate increased levels of
ETB receptor mRNA and protein. In the human genome,
the 5'-flanking region of the genes encoding the endothe-
lin receptors contain several regulatory elements, like
GATA-motifs and E-boxes [31,32]. This indicates that the
genes might be activated by for example stress related and
inflammatory components.
PKC signaling pathways
This study was aimed to elucidate the role of the PKC and
MAPK signaling pathways in the endothelin ETB receptor
regulation. The PKC antagonists, Ro-32-0432 and bisin-
dolylmaleimide I, each inhibited the increase in sarafo-
toxin 6c contraction and the elevated levels of endothelin
ETB receptor protein and mRNA expression, during organ
culture. PKC signaling pathways has previously been sug-
gested to play a role in the development of cardiovascular
disease. PKC increase oxygen production in the growing
atherosclerotic lesion, leading to apoptosis and plaque
instability [33]. The levels of PKC in the myocardium are
elevated in various models of cardiac hypertrophy [34-
36]. Furthermore, PKC isozymes contribute to different
stages of cardiac fibrosis [37]. Indeed, treatment with a
PKCδ inhibitor has been shown to ameliorate the reper-
fusion injury during primary percutaneous coronary inter-
vention for myocardial infarction [37].
MAPK signaling pathways
The MAPK pathways are thought to act downstream from
PKC in the smooth muscle cell regulatory cascade [19].
MAPKs are a family of serine/threonine kinases which are
associated with vascular smooth muscle cell contraction,
migration, adhesion, collagen deposition, cell growth, dif-
ferentiation and survival [38]. The three major subgroups
of MAPK are p38, ERK1/2 and JNK [39]. In the present
study we found that the p38 MAPK pathway inhibitor,
SB203580 (10 μM), the ERK1/2 pathway inhibitor,
PD98059 (10 μM) and the JNK pathway inhibitor,
SP600125 (10 μM), blocked the up-regulation of the
endothelin ETB receptors in human internal mammary
arteries during organ culture. This is in accordance with
previous studies that have a role for MAPK pathways in
cardiovascular disease. JNK is a stress-activated protein
kinase while ERKs mediate cellular responses initiated by
growth factors. The P38 MAPK pathway is activated by
(A) The levels of endothelin ETB receptor mRNA expression  in human internal mammary arteries, examined using real  time PCR Figure 4
(A) The levels of endothelin ETB receptor mRNA 
expression in human internal mammary arteries, 
examined using real time PCR. (B) Endothelin ETB 
receptor protein expression in human internal mammary 
arteries, examined using Western blot. The arteries were 
either not cultured or cultured in the absence or presence of 
the protein kinase C inhibitors Ro-32-0432 or bisindolyl-
maleimide I. The results are shown as mean values ± S.E.M of 
six experiments. Endothelin ETB mRNA levels in cultured and 
non-cultured arteries were compared using Student's t-test, 
where P < 0.05 (*) was considered significant.
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inflammatory cytokines such as TNF-α, IL-1 and IL-8,
which are known to be increased in atherosclerosis and
ischemic heart disease. Since the vessels were obtained
from severely diseased patients the current data may sug-
gest that there is activation of all three major MAPKs in
advanced cardiovascular disease.
Clinical relevance
Endothelin induces strong vasoconstriction in human
blood vessels and endothelin receptors are up-regulated
in cardiovascular disease such as hypertension, arterio-
sclerosis and myocardial infarction. Whether endothelin
receptor antagonists will become part of the therapeutic
armamentarium in hypertension and associated cardio-
vascular disease remains unclear. However, none of these
agents is currently being developed for this indication.
New endothelin antagonists devoid of side effects or alter-
native inhibitors of the endothelin converting enzymes
may in the future become available to block the endothe-
lin system [40]. Along with previous reports [16-18,41],
the present study shows that the endothelin dependent
vascular contraction and remodeling seem to be depend-
ent on both PKC and MAPK. Inhibition of these intracel-
lular signal tran sduction pathways may become a future
approach for targeting the endothelin system in the pre-
vention of the development of cardiovascular disease.
Conclusion
The present findings demonstrate up-regulated endothe-
lin ETB receptors in human left internal mammary arteries
after organ culture, which is similar to the changes that
occur in cardiovascular disease. The intracellular signal
transduction pathways PKC and p38 MAPK seems to be
involved in the endothelin ETB receptor regulation. Inhib-
iting these intracellular signal transduction pathways may
provide future therapeutic targets for hindering the devel-
opment of vascular endothelin receptor changes in cardi-
ovascular disease.
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Contractile responses elicited by cumulative application of the endothelin ETB receptor agonist sarafotoxin 6c in segments of  human internal mammary arteries Figure 5
Contractile responses elicited by cumulative application of the endothelin ETB receptor agonist sarafotoxin 6c 
in segments of human internal mammary arteries. The arterial segments were either not cultured or cultured in the 
absence or the presence of mitogen-activated kinase (MAPK) pathway inhibitors; (A) the P38 MAPK inhibitor SB203580, (B) 
the ERK1/2 inhibitor PD98059 or (C) the JNK inhibitor SP600125. The results are shown as mean values ± S.E.M of six exper-
iments. Statistical analysis was performed using ANOVA with Dunnett's post-test for multiple comparisons. P < 0.05 (*) and P 
< 0.01 (**) was considered significant. Comparisons were made between the results from arteries exposed to culture with and 
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